Grants and Contracts Details
Retinopathy of prematurity is the foremost cause of blindness in infants in the developed world. Improvement in oxygen level monitoring has led to better control of the oxygen given to premature infants. Despite these advances, ROP continues to be significant public health issue due to the fact that neonatal care advances mean more extremely low weight premature infants are surviving. Current standard of care for infants affected by ROP include laser or cryotherapy to stop the growth of new blood vessels in the eye. Unfortunately, these therapies do not address the underlying mechanism driving the disease. Our current proposal focuses on the use of a selective agent, endorepellin, which may allow for better clinical management of ROP in infants. This initial work seeks to characterize the function of endorepellin in inhibit pathological new vessels in a mouse model ofROP. We propose to assess endorepellin at several time points and dose levels in order to determine the optimal administration. We further propose to examine the distribution of endorepellin as it interacts with blood vessels in the eye. These studies are critically important to understanding the function of endorepellin in the eye. Ifpre-clinical studies are successful, endorepellin clinical application could significantly reduce vision loss due to ROP.
|Effective start/end date||7/1/10 → 6/30/12|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.